NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10656	Companies
226830	Keywords
155290	Articles
120110	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/18/2026 at 14:30, 1 month 11 days ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides, Inc. highlights the urgent need for a broad-spectrum antiviral drug like NV-387 amid an Ebolavirus outbreak in DR Congo and Uganda. NV-387 holds promise as it targets sulfated proteoglycans crucial for viral attachment to cells

NanoViricides NV-387 Antiviral Drug Broad-spectrum Ebolavirus Outbreak
BRIEF

published on 05/15/2026 at 14:40, 1 month 14 days ago

NanoViricides annonce une levée de fonds directe de 2 millions de dollars

NanoViricides Investissement Direct Offre De Titres Investisseur Institutionnel Technologie Antivirale
BRIEF

published on 05/15/2026 at 14:40, 1 month 14 days ago

NanoViricides Announces $2 Million Direct Offering

NanoViricides Securities Offering Direct Investment Institutional Investor Antiviral Technology
PRESS RELEASE

published on 05/15/2026 at 14:35, 1 month 14 days ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces a registered direct offering of common shares and warrants to a fundamental institutional investor for gross proceeds of approximately US$2 million. D. Boral Capital LLC acts as the exclusive placement agent for the Offering

NanoViricides Securities Purchase Agreement Registered Direct Offering D. Boral Capital LLC Fundamental Institutional Investor
BRIEF

published on 05/15/2026 at 14:05, 1 month 14 days ago

NanoViricides fait état de progrès dans le développement du NV-387 dans son dernier document déposé auprès de la SEC.

NanoViricides NV-387 Essai De Phase II Médicament Orphelin Traitement De La Variole Du Singe
BRIEF

published on 05/15/2026 at 14:05, 1 month 14 days ago

NanoViricides Reports Progress on NV-387 in Latest SEC Filing

NanoViricides NV-387 Phase II Trial Orphan Drug Monkeypox Treatment
PRESS RELEASE

published on 05/15/2026 at 14:00, 1 month 14 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC. NV-387 advances in Phase II trial for Measles, MPox, and Smallpox treatments. Financial updates disclosed

NV-387 Form 10-Q NanoViricides Inc. Phase II Trial Financial Update
BRIEF

published on 05/11/2026 at 14:35, 1 month 18 days ago

NanoViricides Highlights Need for Broad-Spectrum Antivirals Post-Hantavirus Incident

NanoViricides NV-387 Broad-spectrum Antiviral Hantavirus MV Hondius
BRIEF

published on 05/11/2026 at 14:35, 1 month 18 days ago

NanoViricides souligne le besoin d'antiviraux à large spectre après l'incident du hantavirus

NanoViricides NV-387 Antiviral À Large Spectre Hantavirus MV Hondius
PRESS RELEASE

published on 05/11/2026 at 14:30, 1 month 18 days ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
NanoViricides, Inc. highlights the need for a revolutionary antiviral drug like NV-387 as response to Andes hantavirus incident on a cruise ship, emphasizing potential global epidemic risk

NV-387 NanoViricides Inc. Antiviral Drug Andes Hantavirus Global Epidemic

Accesswire

Published on 06/29/2026 at 15:00, 4 hours 17 minutes ago

Infield Minerals Significantly Expands Land Holdings and Builds Regional Presence at the Detroit Gold Project in Utah
Published on 06/29/2026 at 15:00, 4 hours 17 minutes ago

Vox Royalty Highlights Significant Gold Offtake-Stream Exposure to Los Filos Following Key Milestone Announcement
Published on 06/29/2026 at 14:30, 4 hours 47 minutes ago

Unusual Machines Added to Russell 2000(R) Index
Published on 06/29/2026 at 14:30, 4 hours 47 minutes ago

Sekur Private Data Makes First Intl. Call on SekurOne - Launches SekurOne for Android and Web
Published on 06/29/2026 at 14:30, 4 hours 47 minutes ago

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

View all ACCESSWIRE

EQS Group

Published on 06/29/2026 at 19:00, 17 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 22 JUIN 2026 au 26 JUIN 2026
Published on 06/29/2026 at 18:15, 1 hour 2 minutes ago

E-PANGO: Assemblée générale du 29 juin 2026
Published on 06/29/2026 at 17:57, 1 hour 20 minutes ago

EQS-Adhoc: H&R GmbH & Co. KGaA: Earnings performance significantly exceeding expectations in the second quarter of 2026 – potential target achievement already by mid-year
Published on 06/29/2026 at 17:45, 1 hour 32 minutes ago

Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 06/29/2026 at 16:48, 2 hours 28 minutes ago

Amprion successfully signs €6.5 billion “Energiewende Green Revolving Credit Facility”

Les Echos

Published on 06/29/2026 at 18:30, 47 minutes ago

Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
Published on 06/29/2026 at 18:30, 47 minutes ago

Accor et H World Group : extension du partenariat de long terme aux plateformes de réservation directe et de fidélité
Published on 06/29/2026 at 17:45, 1 hour 32 minutes ago

Successful issue of a € 1.5 billion bond
Published on 06/29/2026 at 17:45, 1 hour 32 minutes ago

Succès de l’émission obligataire de 1,5 milliard d’euros
Published on 06/29/2026 at 17:45, 1 hour 32 minutes ago

Déclaration hebdomadaire de rachat d'actions

View all LES ECHOS COMFI WIRE